If you need more lookups,
subscriptions start at $34 USD/month.
Karim Dabbagh Location
South San Francisco, CA, US
Karim Dabbagh Work
Chief Executive Officer and Board member @ (May 2026 - Present)
Executive Chairman and Co-founder @ Genevive (February 2023 - Present)
President and CEO and Board member @ (September 2024 - May 2026)
Chairman of the Board of Directors @ (June 2023 - June 2025)
President and CEO @ (September 2018 - September 2023)
Chief Scientific Officer @ (August 2014 - December 2020)
Vice President and Head External R and D Innovation and Head Immunology and Immune regulation Department @ (November 2010 - August 2014)
Co-founder and CEO @ ModusBiomedicine (August 2009 - December 2010)
Head of Inflammation Pharmacology @ (April 2001 - December 2009)
Karim Dabbagh Education
Stanford University
Research Fellow
1999-2001
University of Califonia, San Francisco
Postdoctoral Fellow
1997-1999
UCL
PhD
1994-1997
Imperial College of Science, Technology and Medicine
BSc (Hons)
1990-1993
Université Claude Bernard Lyon 1 1989-1990
Karim Dabbagh Skills
Antibodies
Biochemistry
Biopharmaceuticals
Biotechnology
Business Development
Clinical Development
Drug Development
Drug Discovery
Endocrinology
Immunology
Leadership
Life Sciences
Medical Devices
Molecular Biology
Neurology
Oncology
Pharmaceutical Industry
Pharmacology
R&D
Science
Start-ups
Strategy
Microsoft Excel
Start Ups
Project Management
Strategic Planning
Karim Dabbagh Summary
Karim Dabbagh, based in South San Francisco, CA, US, is currently a Chief Executive Officer and Board member at Dualitas Therapeutics. Karim Dabbagh brings experience from previous roles at Genevive, Silver Creek Pharmaceuticals, MaaT Pharma and Second Genome Inc.. Karim Dabbagh holds a 1999 - 2001 Research Fellow @ Stanford University. With a robust skill set that includes Antibodies, Biochemistry, Biopharmaceuticals, Biotechnology, Business Development and more. Karim Dabbagh has 3 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Karim Dabbagh?
Find contact details for 700 million professionals.